We are live on ! Find out more
HCM

Hayman Capital Management Portfolio holdings

AUM $63.3M
1-Year Est. Return 3.78%
This Fund
S&P 500
This Quarter Est. Return
-16.59%
1 Year Est. Return
-3.78%
3 Year Est. Return
-44.06%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$217M
AUM Growth
-$631M
Cap. Flow
-$564M
Cap. Flow %
-260.5%
Top 10 Hldgs %
92.87%
Holding
48
New
8
Increased
5
Reduced
1
Closed
34

Top Buys

Rank Stock Value
1
IPXL
Impax Laboratories, Inc.
IPXL
+$27.3M
2
CF icon
CF Industries
CF
+$27M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$23.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$16M
5
NMIH icon
NMI Holdings
NMIH
+$15.4M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$155M
2
VTRS icon
Viatris
VTRS
+$39.1M
3
CHRD icon
Chord Energy
CHRD
+$18.7M
4
WLL
Whiting Petroleum Corporation
WLL
+$18.6M
5
NFX
Newfield Exploration
NFX
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 35.48%
2 Financials 25.86%
3 Materials 9.62%
4 Energy 3.37%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMIH icon
1
NMI Holdings
NMIH
$3.38B
$56M 25.86%
7,371,500
+1,875,000
+34% +$15.4M
YPF icon
2
CALL
YPF Sociedad Anonima American Depositary Shares (Each representing ten (10) Class D shares of Capital Stock)
YPF
$19.1B
$34.3M 15.82%
2,250,000
+1,000,000
+80% +$22.4M
IPXL
3
DELISTED
Impax Laboratories, Inc.
IPXL
$21.4M 9.86%
+606,618
New +$27.3M
CF icon
4
CF Industries
CF
$17.9B
$20.8M 9.62%
+464,101
New +$27M
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$19.3M 8.89%
+210,715
New +$23.4M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.6B
$13.6M 6.3%
129,501
+119,615
+1,210% +$16M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$123B
$10.4M 4.81%
100,000
+91,051
+1,017% +$11.7M
DBVT
8
DBV Technologies
DBVT
$843M
$9.45M 4.36%
+26,538
New +$10.4M
SRRA
9
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$8.66M 4%
+10,555
New +$11.9M
ESES
10
DELISTED
Eco-Stim Energy Solutions Inc. Common Stock
ESES
$7.31M 3.37%
+2,130,000
New +$8.36M
AGN
11
DELISTED
Allergan plc
AGN
$4.84M 2.23%
+17,813
New +$5.47M
ARCT icon
12
Arcturus Therapeutics
ARCT
$177M
$3.78M 1.74%
+89,399
New +$4.7M
ENDP
13
DELISTED
Endo International plc
ENDP
$3.65M 1.68%
52,634
+27,855
+112% +$2.23M
VTRS icon
14
Viatris
VTRS
$20.6B
$3.18M 1.47%
78,905
-701,346
-90% -$39.1M
BHC icon
15
Bausch Health
BHC
$2.35B
– –
-10,198
Closed -$2.27M
CHRD icon
16
Chord Energy
CHRD
$7.32B
– –
-1,178,332
Closed -$18.7M
CIVI
17
DELISTED
Civitas Resources
CIVI
– –
-7,222
Closed -$14.7M
EOG icon
18
EOG Resources
EOG
$70.4B
– –
-163,860
Closed -$14.3M
FANG icon
19
Diamondback Energy
FANG
$52.1B
– –
-217,149
Closed -$16.4M
GM icon
20
General Motors
GM
$78.2B
– –
-125,967
Closed -$4.2M
HAL icon
21
Halliburton
HAL
$26.5B
– –
-267,148
Closed -$11.5M
HP icon
22
Helmerich & Payne
HP
$3.33B
– –
-142,616
Closed -$10M
IWM icon
23
PUT
iShares Russell 2000 ETF
IWM
$82.5B
– –
-1,500,000
Closed -$187M
LLY icon
24
Eli Lilly
LLY
$1.04T
– –
-15,529
Closed -$1.3M
MRK icon
25
Merck
MRK
$317B
– –
-37,103
Closed -$2.02M
1
2

Similar funds

LVP
Limestone Value Partners Houston, Texas $64M AUM 4.56% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
SVP
Springbank Value Partners Hampton Bays, New York $65.5M AUM 35.56% 1-Year Est. Return
HWM
Heartwood Wealth Management London, United Kingdom $58.9M AUM 14.96% 1-Year Est. Return
CCG
Crescent Capital Group Los Angeles, California $56.8M AUM 11.67% 1-Year Est. Return
CSM
Central Square Management Naperville, Illinois $56.6M AUM 27.75% 1-Year Est. Return
KCP
Keane Capital Partners Charlotte, North Carolina $56M AUM
EL
Elberon LLC Austin, Texas $56M AUM 14.07% 1-Year Est. Return

Hayman Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Hayman Capital Management held 48 positions worth $217M, down 74% from $847M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Hayman Capital Management withdrew a net $564M in Q3 2015, closing 34 positions and reducing 1 holding. Its most notable exit was Perrigo, an estimated $155M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 26% a quarter earlier, followed by Financials and Materials.

Against the trend, Hayman Capital Management opened a new position in Impax Laboratories, Inc. worth $21.4M.

  • Hayman Capital Management's largest Q3 2015 buy was Impax Laboratories, Inc.: 606,618 shares worth $21.4M.
  • Hayman Capital Management added most to BioMarin Pharmaceuticals in Q3 2015, an estimated $16M increase.
  • Hayman Capital Management's biggest Q3 2015 reduction was Viatris, cutting an estimated $39.1M.
  • Hayman Capital Management fully exited Perrigo in Q3 2015, selling an estimated $155M.
  • Hayman Capital Management's ten largest holdings make up 93% of its $217M portfolio in Q3 2015.
  • Hayman Capital Management opened 8 new positions and closed 34 in Q3 2015.
  • Hayman Capital Management's portfolio value fell 74% quarter-over-quarter to $217M.

Based on Hayman Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.